Document is current
Any future updates will be listed below
-
Authors
Kok, Eloise H.
Savola, Sara
Raunio, Anna
Oinas, Minna
Tuimala, Jarno
Polvikoski, Tuomo
Kero, Mia
Kaivola, Karri
Tienari, Pentti J.
Paetau, Anders
Myllykangas, Liisa https://orcid.org/0000-0002-2237-5466
-
Funding
Funding for this research was provided by:
Terveyden Tutkimuksen Toimikunta (294817)
Helsingin ja Uudenmaan Sairaanhoitopiiri (TYH2020231)
Helsingin ja Uudenmaan Sairaanhoitopiiri (TYH2018217)
Medicinska Understödsföreningen Liv och Hälsa
Suomen Kulttuurirahasto
University of Helsinki including Helsinki University Central Hospital
- License Information
-
More Information
Article History
Received: 6 June 2021
Revised: 16 August 2021
Accepted: 21 August 2021
First Online: 1 September 2021
Declarations
:
: Pentti J. Tienari holds a patent on C9orf72 in diagnostics and treatment of ALS/FTD and has made paid consultations to Roche, Biogen, Merck, Teva, Sanofi-Genzyme and Novartis. Other authors declare no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants or their relatives.
